DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.


Check here our latest Investor Presentation.

View deck


Access our recent and upcoming events.

Click here

Upcoming Events

No current upcoming events

Stock Information

Frequently asked questions

Click below to see answers to the most commonly asked questions about investing in CorMedix.

Read more